Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies
Open Access
Abstract
The role of immunotherapy in oncohematology is well established. Monoclonal antibodies have undergone substantial development in recent years, targeting a wide range of molecules (including surface antigens, immune checkpoints, and cytokines) and have demonstrated clinical utility across various hematologic malignancies, including leukemias, lymphomas, and myelomas. The emergence of advanced therapy medicinal products (ATMPs), particularly chimeric antigen receptor (CAR) T cells, has provided an additional and promising therapeutic option. This rapidly evolving field continues to expand therapeutic possibilities. The objective of this literature review is to summarize novel immunotherapeutic strategies in oncohematology, including monoclonal antibody- and CAR T-cell-based approaches, and to review the key findings from recent clinical trials.Keywords
This publication has 193 references indexed in Scilit:
- In vivo CAR therapies: Turning the patient into their own CAR factoryHemaSphere, 2026
- Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary AnalysisAmerican Journal of Hematology, 2026
- Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translationAnnals of Hematology, 2026
- Exploring SLAMF5/CD84 in Cancer: Advancing the Frontiers of Tumor ImmunologyCell Biology International, 2025
- Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemiaCancer Medicine, 2023
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Belantamab Mafodotin: First ApprovalDrugs, 2020
- Correction to: Isatuximab: First ApprovalDrugs, 2020
- Polatuzumab Vedotin: First Global ApprovalDrugs, 2019
- A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701Cancer, 2013